Why the study?
Hypoxic injury contributes critically to various cardiovascular diseases, and mitochondrial quality control is vital for protecting cardiomyocytes from such hypoxic damage.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May support mitochondrial-targeted agents in hypoxia-related CVD; leaves open confirmation in prospective trials.
Hypoxic injury is a critical pathological factor in the development of various cardiovascular diseases, such as congenital heart disease, myocardial infarction, and heart failure. Mitochondrial quality control is essential for protecting cardiomyocytes from hypoxic damage. Under hypoxic conditions, disruptions in mitochondrial homeostasis result in excessive reactive oxygen species (ROS) production, imbalances in mitochondrial dynamics, and initiate pathological processes including oxidative stress, inflammatory responses, and apoptosis. Targeted interventions to enhance mitochondrial quality control, such as coenzyme Q10 and statins, have shown promise in mitigating hypoxia-induced mitochondrial dysfunction. These treatments offer potential therapeutic strategies for hypoxia-related cardiovascular diseases by regulating mitochondrial fission and fusion, restoring mitochondrial biogenesis, reducing ROS production, and promoting mitophagy.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: